Impacts of Metabolic and Mitochondrial Reprogramming on ADPKD Drug Targets and Repurposing

Read the full article

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a complex disorder characterized by the progressive development of renal cysts. Disease progression is linked to ADPKD-driven metabolic and mitochondrial reprogramming that exacerbates ADPKD pathophysiology by impairing central energetic pathways, including mitochondrial respiration and glucose, lipid, and amino acid metabolism. Caloric intake interventions can attenuate disease progression, but are difficult for patients to achieve and limited in application. Given the extensive alterations that impact ADPKD drug targets (i.e., mammalian target of rapamycin (mTOR) signaling pathway, peroxisome proliferator–activated receptor (PPAR) family, etc.) and drug metabolism (i.e., pharmacokinetics, cytochrome P450 (CYP450) family, etc.), improved understanding of the mechanisms driving metabolic and mitochondrial reprogramming may foster the identification of novel ADPKD severity-modifying drug targets and/or drugs. Such drugs could synergistically complement tolvaptan (the only U.S. Food and Drug Administration (FDA)-approved ADPKD therapeutic), or serve as alternatives, as tolvaptan is costly and associated with hepatotoxicity. Repurposing FDA-approved drugs could accelerate translation to clinical practice by leveraging prior work to improve the traditional drug development pipeline. To facilitate identification of repurposed drugs for ADPKD, we review ADPKD-driven metabolic and mitochondrial reprogramming from the perspective of drug target identification for repurposing ADPKD therapeutics.

Article activity feed